India Pharmaceuticals & Clinical Research Reservations open Page created Nov 16, 2026

List of Indian API Manufacturers with US FDA DMFs

Indian active pharmaceutical ingredient (API) manufacturers that hold Type II Drug Master Files with the US FDA, resolved from per-file DMF holder names to the operating company, for generic drug sourcing teams qualifying ANDA suppliers and second sources.

Fields we plan to include

Manufacturer
US DMF position (company-published)
APIs with Type II DMFs
DMF numbers
DMF activity status (A/I)
Headquarters city and state
API manufacturing sites
Other filings (CEP / EDMF / JDMF)
Therapeutic focus
Company website

Data Preview

* Free sample rows, unverified and may contain errors. This list isn't for sale yet.
ManufacturerUS DMF position (company-published)
Neuland LaboratoriesSourceApixaban: USDMF, DMF filed
Supriya Lifescience Ltd.SourceSalbutamol Sulphate: US DMF 030708
Hikal Ltd.SourceGabapentin and Pregabalin: USDMF
MSN LaboratoriesSource570+ API USDMFs
Jubilant PharmaSource65 US DMFs

Estimated ~400 entries. If people reserve it, we'll try to compile it (we can't compile every list).

* No charge now. Purchase is optional.

Indian API manufacturers in the US FDA Drug Master File system

India is one of the largest sources of active pharmaceutical ingredients for US generic medicines, and the Type II Drug Master File (DMF) is the document that connects an Indian API plant to a US Abbreviated New Drug Application (ANDA). A DMF lets the API maker submit confidential chemistry, manufacturing and controls (CMC) information directly to FDA, so the finished-dose applicant can reference it through a Letter of Authorization without ever seeing the proprietary process.

How the FDA DMF list is organised

FDA publishes its list of DMFs as an Excel workbook and posts a new edition each quarter. The edition posted in October 2026 ("3rd Quarter 2026") is current through DMF 044931 and records each file's number, status, type, submission date, holder name and subject. The list is organised per file, not per company, which is where sourcing teams lose time:

  • Holder names vary. The same group can appear as a parent company, a renamed entity, an acquired subsidiary or a holder spelled several ways across decades of submissions.
  • Status matters. Files are marked active (A) or inactive (I). An inactive file cannot support a new ANDA reference until it is reactivated.
  • Type matters. Type II covers drug substances, intermediates and the material used to make them; Type III (packaging), Type IV (excipients) and Type V (other) are not API supplier files.
  • Subjects are free text. The same API can be described with or without salt form, hydrate, polymorph or process qualifiers (for example "crystalline", "amorphous" or "sterile").

Completeness assessment and GDUFA fees

Under the Generic Drug User Fee Amendments (GDUFA), a Type II API DMF holder pays a one-time DMF fee when the file is first referenced by a generic application, after which FDA performs an initial completeness assessment. Files that pass are posted on FDA's separate list of Type II API DMFs available for reference. For a buyer, "has a DMF" and "has a DMF that has passed completeness assessment and is available for reference" are different levels of readiness: the second shortens the path for a new ANDA.

What sourcing teams check before qualifying an Indian supplier

CheckWhy it matters
Active Type II DMF for the exact salt and formThe ANDA must reference a file covering the specific drug substance being used.
GDUFA fee paid / available for referenceIndicates the file has passed FDA's completeness assessment.
Inspection history of the API siteFDA warning letters and import alerts on Indian API plants directly affect supply continuity.
Parallel filings (CEP, EDMF, JDMF, KDMF)Suppliers filed in several markets are easier to use across a global portfolio.
Backward integrationCaptive key starting materials and intermediates reduce exposure to single-country raw-material risk.

Where the Indian API base is concentrated

The Indian holders sit in established API hubs such as Hyderabad in Telangana, the Mumbai–Thane belt and MIDC industrial estates of Maharashtra, and the National Capital Region around Noida. Holders range from integrated generic groups with hundreds of US filings to focused mid-size producers whose DMFs cover a few niche molecules. The companies in the sample illustrate this range: MSN Laboratories states it holds more than 570 API US DMFs, Jubilant Pharma cites 65 US DMFs, and specialist producers such as Supriya Lifescience publish individual DMF numbers on product pages.

Using DMF holders for second sourcing

Second-sourcing an API for an approved ANDA requires a prior approval or CBE supplement that references the new supplier's DMF, plus comparative data on impurity profile, particle size and polymorphic form. Teams therefore shortlist holders whose active Type II files cover the same form, then contact them for a Letter of Authorization, the open part of the DMF and site audit reports. Mapping holders to operating companies is what turns the FDA file list into a usable supplier shortlist.

Frequently Asked Questions

Q.What is the difference between a Type II DMF and a CEP?

A Type II DMF is a confidential file submitted to the US FDA and reviewed only when a drug application references it. A Certificate of Suitability (CEP) is issued by the EDQM after it assesses the substance against the European Pharmacopoeia monograph, and it is used for European and many other markets.

Q.What does 'available for reference' mean for a Type II API DMF?

Under GDUFA, once the holder pays the DMF fee FDA runs an initial completeness assessment. Files that pass are posted on FDA's list of Type II API DMFs available for reference, meaning a generic applicant can cite them in an ANDA.

Q.Can an ANDA reference an inactive DMF?

No. An inactive DMF must be reactivated by the holder, typically by submitting an annual report or update, before it can support a new reference.

Q.What does a generic company need from the API supplier besides the DMF number?

A Letter of Authorization allowing FDA to review the DMF on the applicant's behalf, the applicant's (open) part of the DMF, certificates of analysis, and usually a quality audit of the manufacturing site.

Q.Can I buy the list now?

Not yet. Sample rows are free. We try to compile lists that people reserve (we can't compile every list). If we do, we'll email everyone who reserved it a purchase link (buying is optional). If we don't, nothing happens and you're never charged.

Q.What does it cost?

Sample rows are free. A list is $49, paid only if we compile it and you decide to buy. There is no free trial or subscription.